Altamira Therapeutics Ltd. Stock Price: Quote, Forecast, Splits & News (CYTO)

Company Profile

Altamira Therapeutics Ltd. Price & Performance (CYTO)

Stock Performance

Updated Jan 16, 9:00 PM UTC

Altamira Therapeutics Ltd.

$0.30USD

-$0.71 (-70.3%)

After Hours

-$0.30 (-100%)

Prev Close

$0.30

Market Cap

$1.13M

Day Range

$0.30 - $0.42

Open

$0.42

P/E Ratio

0.2

52W Range

$0.07 - $3.49

24H Volume

$217.29K

Dividend Yield

0.00%

EPS

1.82

Latest News

Altamira Therapeutics Schedules June 2025 Annual General Meeting Amid Stock Pressure
May 9, 2025
Altamira Therapeutics has announced its Annual General Meeting for June 2025, providing shareholders with updates on governance and strategy. The company’s stock remains near its 52-week low after a 47% decline over the past year, despite modest revenue growth and ongoing compliance with U.S. SEC reporting requirements.12
Swiss Biotech Firm Altamira Advances RNA Delivery and Eyes Spin-Out to Boost Growth
Apr 29, 2025
Altamira Therapeutics reported progress on its xPhore RNA delivery platform, highlighting early validation and new collaborations. To fund further development, the company plans to partially spin out its RNA business to private equity, aiming to reduce reliance on dilutive capital raises and streamline operations for 2025.3
Auditor Flags ‘Going Concern’ Uncertainty for Altamira Despite Strategic Moves
Apr 29, 2025
Altamira Therapeutics’ latest annual report includes an auditor’s warning about its ability to continue as a going concern. The company has responded with a cost-cutting strategy and plans for a business spin-out, but financial pressures and a widening net loss remain key risks for investors to monitor.43

What's Happening

Peers

Earnings

Report Date

—

Rev Estimate

—

Avg 1d Change

4.59%

Report Period

H2 2024

EPS Estimate

—

Implied Move 1d

—

Transcript

9m 29s

Good morning, and welcome to the Altamira Therapeutics Full Year twenty twenty four Financial Results Business Update Call. On today's call are Thomas Meyer, Altamira's Founder Chairman and Chief Executive Officer and Covadonga Pineda, Altamira's chief operating officer Earlier today, Altamira issued a news release with the full year 2024 financial results as well as a business update. The release is available on the company's website at www.altamiratherapeutics.com. And has been filed with the SEC. During today's call, the company will be making forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements that address future operating financial or business performance or strategies or expectations. Forward looking statements are based on management's current expectations, and beliefs and involve significant risks and uncertainties that could cause actual results, developments, and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to the timing and conduct of our clinical trials clinical utility of our product candidates, the timing or likelihood of regulatory filings and approvals, our intellectual property position, and our financial position. As well as those described in the risk factors section in our annual report on Form 20 f and future filings with the Securities and Exchange Commission.

11m 5s

In addition, any forward looking statements represent the company's views only as of today and should not be relied upon as representing its views as of any subsequent date. While it may elect to update these forward looking statements at some point in the future, It specifically disclaims any obligation to do so even if it's for you to change. With that, I will now hand the call over to Altamira Therapeutics CEO, Thomas Meyer.

11m 30s

Thank you, operator.

11m 32s

Hello, everyone, and thank you for joining our full year 2024 financial results and business update call. I will kick off the call by providing an overview of recent corporate developments and an update of our corporate strategy. Our Chief Operating Officer, Kua Dong Panida, will then discuss the progress with our RNA delivery business. Finally, I will discuss our 2024 financials, and outlook for 2025. Overall, 2024 brought progress in many regards for Altamira. With our RNA delivery programs, we continued to gain momentum as we could win two new partners for our X4 platform, managed to further improve our manufacturing process and were able to demonstrate that the platform works also with circular RNA. The latter highlighted the platform's great versatility across different RNA modalities and could help to open interesting new business opportunities for Altamira. Unfortunately, there was also a major setback in 2024 as NASDAQ decided to delist our common shares due to an issue with their minimum bid price rules. Also, we appealed against their decision and proposed taking customary measures to regain compliance our arguments fell on deaf ears. And the NASDAQ hearing panel upheld delisting decision. Therefore, trading in our common shares was transferred to OTCQB and the ticker symbol changed from cyto to cytoF.

13m 27s

The transfer and the changes in valuation and trading volume related to this triggered our Board to perform an intense review of the company's funding needs and options. We concluded that raising funding for the expected growth of the RNA delivery business from public markets was not a viable option.

13m 52s

Rather, the Board decided to prepare the involvement of private equity investors at the level of the company's Swiss subsidiary Altamira Therapeutics AG short ATAG, which operates Altamira's RNA delivery business. Altamira aims to spin off a majority of ATAG's share capital and has initiated a process for the legal and organizational carve out of this entity. With the partial spin off, we anticipate the publicly listed Altamira Therapeutics Limited becoming even more of a holding company owning minority stakes, in ATAG, and Altamira Medica the manufacturer of the bench or nasal spray, and participating in their expected growth and value appreciation. In addition, the listed parent company stands to benefit from the partnering of the other legacy assets such as AM-one hundred twenty five, our nasal spray for vertigo treatment, or AM-one hundred eleven. A treatment for acute hearing loss. Following this introduction and update, I'm handing the call over to Kowadonga Panida, our Chief Operating Officer, who will provide you with a more detailed update on our RNA delivery business. [indiscernible] Thanks, Thomas, and good morning, everyone. RNA therapeutics continues to be an exciting space. With more drugs and modalities reaching late stage clinical programs and market approval.

15m 37s

Research and development activities in Altamira Therapeutics peptide based X4 nanoparticle platforms continues to progress. The key focus during the first half of the year was the nanoparticle formulation and process development around our platform.

15m 54s

Oligo-four for siRNA, semaphore for mRNA, and Cyclophore the newest addition to our technology for circular RNA. In addition, significant effort has been allocated into evaluation and development of nanoparticles to deliver specific RNA payloads for our partners. Important progress has been achieved with the development and refinement of analytical methods reproducibility of manufacturing and stability of a nanoparticle. Our efforts have led to nanoparticles with greater stability that can be shipped and stored while maintaining their physical chemical properties. In addition, tolerability studies have shown that these particles have an excellent tolerability profile. After a single or repeated intravenous administration. Circling back to the newest member of the X4 family, we are excited over the confirmation that our technology is amenable for use with circular RNA. In vitro experiments demonstrated successful cell leading to higher protein expression compared with linear mRNA. Based on these results, the company filed a provisional patent application with the United States Patent Office with five zero four.

17m 15s

Circular RNA has recently attracted substantial interest in drug development thanks to enhanced protein expression, and greater stability compared to linear mRNA. Cycle four could open up new collaboration of opportunities with companies focused on this particular RNA modality or seeking to treat chronic diseases. Altamira is pursuing a picks and shovels strategy with the RNA delivery business. This strategy is based on the licensing of our platform technology to partners in the biotech and pharma industry for use with their own RNA payload. To the already established collaborations with Hackett Therapeutics, for regeneration of damaged heart tissue following myocardial infarction. And Universal's group for mRNA vaccines have added a new collaboration agreement this time with a company in the radiopharmaceutical sector, evaluate the use of Altamira's proprietary RNA delivery platform for radiopharmaceutical targeting. Radiopharmaceutical therapy uses very small amounts of radioactive compounds. Called radiopharmaceuticals or radioligands. To diagnose and treat various diseases, in particular, cancer. Once injected into the patient, the radiopharmaceutical finds its way to the tumor to the bloodstream, combines to a tumor specific receptor. The global radiopharmaceutical market reach 8,400,000,000.0 US dollars in size in 2024, and is expected to grow to 17,100,000,000.0 US dollars in 02/1933.

18m 57s

Under the terms of the agreement, Altamira and its project collaboration partner intend to test in vitro and in vivo the use of nanoparticles with an undisclosed RNA payload in conjunction with one of the partner's proprietary radiopharmaceuticals. Upon successful conclusion, of the experiment, the partner will, under certain conditions, have the option to negotiate with Altamira a license and supply agreement to develop, commercialize the RNA particles for use in cancer treatment. Focusing on our proprietary developmental program, AM-four zero one and AM-four 11, Altamira five during the first half of twenty twenty four, several patent applications with the US Patent and Trademark Office to protect candidates for both programs. For AM four zero one, we have now shown that their candidate based on oligo4 platform is well tolerated after intravenous administration even at high doses. The company aims to advance at least one of the flagship programs to an investigational new drug IND filing with the Food and Drug Administration in 2026. And to outlicense them either following the IND or after phase one clinical trial at the latest. In August 2024, part of the company's expanding research and developmental team moved to the Switzerland Innovation Park in Asheville.

20m 32s

Near Basel. At the new location, the company has access to modern and well equipped lab facilities to support its going activities. I will now turn the call back to Thomas.

20m 46s

Thanks, Koba. I will now discuss briefly our two main legacy assets. The Bencio drug free nasal spray for allergy, and our 25 BetaHist nasal spray for vertigo and other disorders. Of the central nervous system. Our associate Altamira Medica or short Medica, agreed last year with two of its international distributors on the expansion of the exclusive distribution territories. With Neon Pharma for Southeast Asia and with Pharma Nordic for Sweden and Denmark. The two territory extensions are a strong mutual vote of confidence by the partners. This year, Medica expects marketing approval for Benzio in Mainland China providing for a major commercial opportunity in cooperation with Neos. Pharma. For The U. S, the world's largest market for over the counter products for allergic rhinitis relief and treatment, Medica recently received good news from the U. S. Patent and Trademark Office The USPTO finally allowed a patent covering venturous composition providing for market protection up to 2,040. This has been the last important missing piece in discussions with potential U. S. Licensees or distributors as Ventura has already been cleared by the FDA. Discussions with potential partners are ongoing. Meanwhile, in Europe, Medic has been working hard on setting up an alternate production site with a contract manufacturer in Germany, and on transitioning Benchyo from a Class I to a Class IIa medical device under the new EU medical device Regulation, MDR.

22m 39s

The completion of these two projects will open up significant commercial opportunities in Europe and allow for ramping up supplies to partners worldwide. As for our AM-one 25 nasal spray, we have partnering discussions ongoing with several parties. The same goes for AM-one 11, a self penetrating peptide for the treatment of acute hearing loss, which has orphan drug designation, and is in phase three clinical development. Now turning to our financials. Before reviewing our financial results for 2024, I would like to note that the full year financial statements are presented for the first time in U. S. Dollars rather than in Swiss francs. Further, I need to remind everyone that due to the partial divestiture of Medica, the bencher activities are reported as discontinued operations. Continuing operations does comprise the RNA delivery development programs as well as those related to AM 125. Overall, financial results for 2024 came in pretty much within expectations. Total operating loss from continuing operations increased from $6,600,000 in 2023 to $6,900,000 2024. Research and development expenses were $3,700,000 in 2024, versus $3,400,000 in 2023. General and administrative expenses decreased from $3,500,000 in 2023 to $3,200,000 in 2024. Net finance expense decreased from $1,500,000 in 2023 to $800,000 in 2024, primarily as the company incurred no more interest expenses.

24m 55s

They worked in 2023, 1,100,000.0. The company's share of the loss of its 49% associate Altamira Medica amounted to $800,000 in 2024 versus $44,000 in 2023 However, the latter related only to the period from the sale of 51% of Medica's share capital in November 2023 to year end. The company's net loss for 2024 was $8,500,000 compared with $4,300,000 in the previous year. However, it must be noted that in 2023, discontinued operations contributed a profit of $3,800,000 reflecting an accounting gain of $5,800,000 on a partial sale of Medica. Overall, the balance sheet as of 12/31/2024, does not show major changes compared to 12/31/2023. Shareholders' equity amounted to $6,600,000 compared with $7,700,000 at year end 2023. There was no financial debt outstanding at either time point. Cash used in operations decreased from $12,800,000 in 2023 to $6,100,000 in 2024. Investing activities consumed $100,000 in cash in 2024, whereas they had provided $1,600,000 in 2023, reflecting mainly the Medicare transaction. Financing activities provided $6,500,000 of cash inflow in 2024 compared against $11,800,000 in 2023. Cash and cash equivalents at year end 2024 rose to $1,000,000 from $700,000 at 12/31/2023. Upon completion of the plant partial spin off of ATAG, our subsidiary for RNA delivery we expect operating expenses to decrease significantly.

27m 23s

The parent company will become, as mentioned earlier, more of a classic holding company, managing and monetizing its participations and assets. We expect to fund our operations from our cash position proceeds from the sale of ATAG shares to private equity investors the partnering or divestiture of legacy assets as well as from the provisional services for affiliates. Resonance from meetings with potential private equity investors has been very encouraging. Altamira intends to update its financial guidance as and when material new information will become available. Notably on the plant partial spin off of ATAG. With this, let me conclude with some comments and perspectives. At the beginning of today's presentation, I mentioned the growing momentum in our RNA delivery business. It is great to see the significant progress that we have been making since the beginning of twenty twenty four both with our development projects as well as with our business development activities. For this momentum to continue or even accelerate further, it will be essential to have the business funded appropriately. The delisting from NASDAQ was undoubtedly a painful experience for all of us, and threw a branch into the works. Especially regarding our ability to raise meaningful capital on the public markets.

28m 59s

With the planned partial spin off of our RNA delivery activities, and the involvement of private equity investors we believe to have found a reasonable and beneficial alternative approach. It will help to position Altamira well for building the business on the strengths of X4 and addressing the strong potential for RNA therapeutics. Also, of the listed parent company will control control less of the RNA delivery business As a result of the spin off, that business itself will be better capitalized and in a stronger position to grow. We certainly still have some work to do, to implement this relatively far reaching restructuring of the company. We look forward to advancing this important project as well as our other projects towards the next milestones and to updating you with further reports about our progress. I thank everyone for attending this morning's call and wish you a terrific day ahead. I would now like to turn the call back to the operator.

30m 13s

Thank you for your participation. In today's conference. This does conclude the program and you may now disconnect. Thank you.

Key Insights

Altamira Therapeutics made significant progress in its RNA delivery business in 2024, including winning two new partners for its X4 platform, improving manufacturing processes, and demonstrating the platform's compatibility with circular RNA, which could open new business opportunities.
The company faced a major setback with the delisting of its common shares from NASDAQ due to minimum bid price rules, resulting in a transfer to OTCQB and a ticker change from CYTO to CYTOF; this prompted a strategic review and a decision to seek private equity investment at the subsidiary level.
Altamira plans to spin off a majority stake in its Swiss subsidiary (ATAG), which operates the RNA delivery business, positioning the parent company as a holding entity with minority stakes in ATAG and Altamira Medica, and focusing on monetizing these participations and legacy assets.
Financially, the company reported a 2024 net loss of $8.5 million (vs. $4.3 million in 2023), with operating losses from continuing operations increasing to $6.9 million; cash used in operations decreased to $6.1 million, and cash at year-end rose to $1 million; no financial debt was outstanding.
Looking ahead, Altamira expects operating expenses to decrease significantly after the ATAG spin-off and plans to fund operations through cash on hand, proceeds from the ATAG share sale, partnering or divestiture of legacy assets, and services for affiliates; financial guidance will be updated as material new information becomes available, particularly regarding the ATAG spin-off.

Recent Transcripts

2024 saw progress in RNA delivery but faced a NASDAQ delisting and business restructuring.

Income Statement

Revenue

	2019	2020	2021	2022	2023
Revenue	-CHF 56K	CHF 174K	CHF 64K	CHF 306K	CHF 0
Cost of Revenue	CHF 0	CHF 0	CHF 2.2M	CHF 1.4M	CHF 0
Gross Profit	-CHF 56K	CHF 174K	-CHF 2.2M	-CHF 1.1M	CHF 0
Gross Profit %	100%	100%	-3.4K%	-372%	0%
R&D Expenses	CHF 3.3M	CHF 2.9M	CHF 8.9M	CHF 20M	CHF 3M

2019

2020

2021

2022

2023

Revenue

-CHF 56K

CHF 174K

CHF 64K

CHF 306K

CHF 0

Cost of Revenue

CHF 0

CHF 2.2M

CHF 1.4M

CHF 0

Gross Profit

-CHF 56K

CHF 174K

-CHF 2.2M

-CHF 1.1M

CHF 0

Gross Profit %

100%

-3.4K%

-372%

R&D Expenses

CHF 3.3M

CHF 2.9M

CHF 8.9M

CHF 20M

CHF 3M

Cash Flow

Net Income

	2019	2020	2021	2022	2023
Net Income	-CHF 6.6M	-CHF 8.2M	-CHF 17M	-CHF 27M	-CHF 3.9M
Dep. & Amort.	CHF 31K	CHF 20K	CHF 76K	CHF 119K	CHF 119K
Def. Tax	-CHF 194K	-CHF 21K	CHF 22K	-CHF 10K	-CHF 100K
Stock Comp.	CHF 227K	CHF 369K	CHF 1.2M	CHF 343K	CHF 0
Chg. in WC	-CHF 1.2M	CHF 301K	CHF 511K	CHF 3.6M	-CHF 4.2M

2019

2020

2021

2022

2023

Net Income

-CHF 6.6M

-CHF 8.2M

-CHF 17M

-CHF 27M

-CHF 3.9M

Dep. & Amort.

CHF 31K

CHF 20K

CHF 76K

CHF 119K

Def. Tax

-CHF 194K

-CHF 21K

CHF 22K

-CHF 10K

-CHF 100K

Stock Comp.

CHF 227K

CHF 369K

CHF 1.2M

CHF 343K

CHF 0

Chg. in WC

-CHF 1.2M

CHF 301K

CHF 511K

CHF 3.6M

-CHF 4.2M

Balance Sheet

Cash

	2019	2020	2021	2022	2023
Cash	CHF 1.4M	CHF 11M	CHF 984K	CHF 15K	CHF 617K
ST Investments	CHF 0	CHF 0	CHF 0	CHF 0	CHF 0
Cash & ST Inv.	CHF 1.4M	CHF 11M	CHF 984K	CHF 15K	CHF 617K
Receivables	CHF 0	CHF 0	CHF 22K	CHF 6.5K	CHF 75K
Inventory	-CHF 988M	-CHF 358M	CHF 839K	CHF 12K	CHF 0

2019

2020

2021

2022

2023

Cash

CHF 1.4M

CHF 11M

CHF 984K

CHF 15K

CHF 617K

ST Investments

CHF 0

Cash & ST Inv.

CHF 1.4M

CHF 11M

CHF 984K

CHF 15K

CHF 617K

Receivables

CHF 0

CHF 22K

CHF 6.5K

CHF 75K

Inventory

-CHF 988M

-CHF 358M

CHF 839K

CHF 12K

CHF 0

Go Deeper

Financial information provided by Financial Modeling Prep. Options data provided by Unusual Whales. Live transcripts provided by Quartr. Reported revenue and EPS data from Earnings powered by FinChat.io. All data is provided for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. · See all tickers.

Overview
Latest News
Earnings
Income Statement
Cash Flow
Balance Sheet
Related

Earnings

Report Date

—

Rev Estimate

—

Avg 1d Change

4.59%

Report Period

H2 2024

EPS Estimate

—

Implied Move 1d

—

Transcript

9m 29s

11m 5s

11m 30s

Thank you, operator.

11m 32s

13m 27s

13m 52s

15m 37s

15m 54s

17m 15s

18m 57s

20m 32s

Near Basel. At the new location, the company has access to modern and well equipped lab facilities to support its going activities. I will now turn the call back to Thomas.

20m 46s

22m 39s

24m 55s

27m 23s

28m 59s

30m 13s

Thank you for your participation. In today's conference. This does conclude the program and you may now disconnect. Thank you.

Key Insights

Altamira Therapeutics made significant progress in its RNA delivery business in 2024, including winning two new partners for its X4 platform, improving manufacturing processes, and demonstrating the platform's compatibility with circular RNA, which could open new business opportunities.
The company faced a major setback with the delisting of its common shares from NASDAQ due to minimum bid price rules, resulting in a transfer to OTCQB and a ticker change from CYTO to CYTOF; this prompted a strategic review and a decision to seek private equity investment at the subsidiary level.
Altamira plans to spin off a majority stake in its Swiss subsidiary (ATAG), which operates the RNA delivery business, positioning the parent company as a holding entity with minority stakes in ATAG and Altamira Medica, and focusing on monetizing these participations and legacy assets.
Financially, the company reported a 2024 net loss of $8.5 million (vs. $4.3 million in 2023), with operating losses from continuing operations increasing to $6.9 million; cash used in operations decreased to $6.1 million, and cash at year-end rose to $1 million; no financial debt was outstanding.
Looking ahead, Altamira expects operating expenses to decrease significantly after the ATAG spin-off and plans to fund operations through cash on hand, proceeds from the ATAG share sale, partnering or divestiture of legacy assets, and services for affiliates; financial guidance will be updated as material new information becomes available, particularly regarding the ATAG spin-off.

Altamira Therapeutics Ltd. Price & Performance (CYTO)

Stock Performance

Prev Close

Market Cap

Day Range

Open

P/E Ratio

52W Range

24H Volume

Dividend Yield

EPS

Prev Close

Market Cap

Day Range

Open

P/E Ratio

52W Range

24H Volume

Dividend Yield

EPS

Latest News

What's Happening

Peers

Earnings

Report Date

Rev Estimate

Avg 1d Change

Report Period

EPS Estimate

Implied Move 1d

Transcript

Key Insights

Recent Transcripts

Income Statement

Cash Flow

Balance Sheet

Go Deeper

Related

Go Deeper

Recent Transcripts

Latest News

Earnings

Report Date

Rev Estimate

Avg 1d Change

Report Period

EPS Estimate

Implied Move 1d

Transcript

Key Insights